Large-Cap Injectable-Focused Pharma Company Gains USFDA Nod for Key Pain Management Drug
With a PE ratio of 36.6, the company trades at a premium compared to the industry PE of 36.4. The company has ROCE of 13.6 per cent and ROE of 9.26 per cent.
Gland Pharma Limited, a leading generic injectable-focused pharmaceutical company, has received approval from the United States Food and Drug Administration (USFDA) for its Acetaminophen Injection, 10 mg/mL (500mg/50mL and 1000mg/100mL) Bags. This product is bioequivalent and therapeutically equivalent to the reference listed drug of B. Braun Medical, Inc. It is indicated for managing mild to moderate pain in adult and paediatric patients aged two years and older, as well as moderate to severe pain with adjunctive opioid analgesics. The company plans to launch this product through its marketing partner soon.
According to IQVIA, the product had US sales of approximately USD 55 million for the twelve months ending February 2025. Gland Pharma, established in 1978 in Hyderabad, has grown into one of the largest injectable-focused companies with a global presence across 60 countries. The company operates primarily under a business-to-business model and has a strong track record in developing, manufacturing, and marketing sterile injectables.
DSIJ's DSIJ's ‘Mid Bridge’ service recommends well researched Mid-Cap stocks for smart investing. If this interests you, do download the service details here.
Gland Pharma, established in 1978 in Hyderabad, has evolved from a contract manufacturer to one of the largest injectable-focused companies globally, with operations in over 60 countries. The company operates primarily under a B2B model, providing a comprehensive range of services, including contract development and technology transfer. Gland Pharma's product portfolio includes over 89 SKUs across 15 therapeutic areas, with significant growth driven by new product launches and strategic acquisitions.
Between FY22 and FY24, the company's revenue grew by 29 per cent, with a 9 per cent increase in H1 FY25. Despite a decline in operating margin from 34 per cent in FY22 to 24 per cent in FY24 due to the integration of Cenexi, the company continues to focus on expanding its manufacturing capabilities and product offerings. Recent strategic initiatives include a partnership with Dr. Reddy's Laboratories for the biologics CDMO business and the establishment of a biologics manufacturing facility in Hyderabad. Gland Pharma's commitment to innovation is evident in its robust R&D efforts, with 363 ANDAs filed in the US and a focus on complex product development.
As of April 04, 2025, Gland Pharma's stock is priced at Rs 1,475. The 52-week High is Rs 2,143.1, and the 52-week Low is Rs 1,440.6. Gland Pharma's market capitalisation stands at Rs 25,292 crore. The company has experienced a 1-year return of -14.18 per cent and a 3-year return of -53.92 per cent.
In the Quarterly Results of December 2024, the company reported a revenue of Rs 1,384.05 crore, reflecting a YoY decline of 10.43 per cent compared to Rs 1,545.16 crore in December 2023. The operating profit stood at Rs 359.96 crore, marking a 1.00 per cent increase from Rs 356.39 crore in the same quarter last year. The profit after tax (PAT) grew by 6.69 per cent to Rs 204.69 crore from Rs 191.86 crore in December 2023.
In FY24, the company posted a revenue of Rs 5,664.72 crore, registering a 56.29 per cent growth compared to Rs 3,624.60 crore in FY23. The net profit for the year stood at Rs 772.46 crore, down 1.10 per cent from Rs 781.04 crore in the previous financial year.
With a PE ratio of 36.6, the company trades at a premium compared to the industry PE of 36.4. The company has ROCE of 13.6 per cent and ROE of 9.26 per cent.
Investors must keep this Large-Cap stock on their radar.
Disclaimer: The article is for informational purposes only and not investment advice.